JNJ-27141491
CAS No. : 871313-59-6
| Size | Price | Stock |
|---|---|---|
| 1mg | $445 | In-stock |
| 5mg | $1335 | In-stock |
| 10mg | $2222 | In-stock |
| 25mg | $4444 | In-stock |
| 50mg | $6666 | In-stock |
| 100mg | $9999 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-110132 |
| M.Wt: | 379.38 |
| Formula: | C17H15F2N3O3S |
| Purity: | >98 % |
| Solubility: | 10 mM in DMSO |
JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human CCR2[1].
In Vitro:JNJ-27141491 inhibits MCP-1-induced [35S]GTPγS binding to hCCR2-CHO cell membranes (IC50=38±9 nM) and reduces MCP-1-induced Ca2+ mobilization in hCCR2-CHO cells (IC50=13±1 nM), in THP-1 cells (IC50=13±2 nM), and in human blood monocytes (IC50=43±4 nM). JNJ-27141491 also inhibits chemotaxis of human PBMC toward MCP-1, with an IC50 value of 97±16 nM[1].
JNJ-27141491 competes with the binding of MCP-1 to hCCR2 and acts as a noncompetitive antagonist of the CCR2 receptor[1].
In Vivo:JNJ-27141491 (5-40 mg/kg; oral; once or twice daily) inhibits recruitment of monocytes and neutrophils into the alveolar air space of transgenic hCCR2 knockin mice[1].
JNJ-27141491 (20 mg/kg; oral; daily for 16 days) delays experimental autoimmune encephalomyelitis (EAE) in transgenic CCR2 mice[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- JNJ-27141491
- Cat. No.:
- HY-110132
- Quantity:
Your information is safe with us.